Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C424S001690
Reexamination Certificate
active
07960334
ABSTRACT:
This invention relates to the use of ADNF III polypeptides in the treatment of mental diseases or disorders, including schizophrenia. Embodiments of the invention provide methods for treating mental disorders, including schizophrenia, in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to reduce or eliminate symptoms. The ADNF III polypeptides include polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain the active core sites and provide neuroprotective and anti-schizophrenic functions.
REFERENCES:
patent: 4587046 (1986-05-01), Goodman et al.
patent: 5767240 (1998-06-01), Brenneman et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6613740 (2003-09-01), Gozes et al.
patent: 6649411 (2003-11-01), Gozes et al.
patent: 6933277 (2005-08-01), Brenneman et al.
patent: 7264947 (2007-09-01), Gozes et al.
patent: 7427598 (2008-09-01), Spong et al.
patent: 7452867 (2008-11-01), Gozes et al.
patent: 7863247 (2011-01-01), Brenneman et al.
patent: 2003/0166544 (2003-09-01), Clark et al.
patent: 2004/0053313 (2004-03-01), Gozes et al.
patent: 2008/0194488 (2008-08-01), Gozes et al.
patent: 2009/0124543 (2009-05-01), Gozes et al.
patent: 2009/0137469 (2009-05-01), Gozes et al.
patent: 2009/0170780 (2009-07-01), Gozes et al.
patent: 2009/0203615 (2009-08-01), Spong et al.
patent: 2010/0216723 (2010-08-01), Gozes et al.
patent: 1 206 489 (2004-05-01), None
patent: WO 92/18140 (1992-10-01), None
patent: WO 96/11948 (1996-04-01), None
patent: WO 98 35042 (1998-08-01), None
patent: WO 98/35042 (1998-08-01), None
patent: WO 00/27875 (2000-05-01), None
patent: WO 00/53217 (2000-09-01), None
patent: WO 01/12654 (2001-02-01), None
patent: WO 01/92333 (2001-12-01), None
patent: WO 2004/080957 (2004-09-01), None
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides, vol. 71, No. 2, (Aug. 15, 1997).
Bedikian, Agop Y., et al., “Phase II Trial of Docetaxel in Patients with Advanced Cutaneous Malignant Melanoma Previously Untreated with Chemotherapy:” Dec. 1995;Journal of Clinical Oncology; Vo. 13; No. 12; pp. 2895-2899.
Bassan, M. et al. “Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry, vol. 72, pp. 1283-1293 (1999).
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998. Abstracts, vol. 23, Part 1, p. 1043 (1998).
Brenneman, D.C. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation, vol. 97, pp. 2299-2307 (1996).
Brenneman et al. “Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide.”Nature335:636 (1988).
Brenneman et al. “N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures”Dev. Brain Res.51:63 (1990).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997. Abstracts, vol. 23, Part 2, p. 2250 (1997).
Brenneman, D.E. et al. “Activity-Dependent Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics, vol. 285, pp. 619-627 (1998).
Brenneman, D.E., et al.; “Protective Peptides Derived from Novel Glial Proteins;” 2000;Biochemical Society Transactions; vol. 28; Part 4; pp. 452-455.
Chiba, Tomohiro et al.; “Neuroprotective Effect of Activity-Dependent Neurotrophic Factor Against Toxicity From Familial Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 in Vitro and in Vivo”; 2004,Journal of Neuroscience Research, vol. 78, pp. 542-552.
Chiba, Tomohiro, et al., “Development of a Femtomolar-Acting Humanin Derivative Named Colivelin by Attaching Activity-Dependent Neurotropic Factor to its N Terminus: Characterization of Colivelin-Mediated Neuroprotection against Alzheimer's Disease-Relevant Insults in Vitro and in Vivo;” Nov. 2, 2005;The Journal of Neuroscience; vol. 25; No. 44; pp. 10252-10261.
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997. Abstracts, vol. 23, Part 2, p. 2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation, vol. 99, pp. 28377-2841 (1997).
Divinski, Inna, et al ., “A Femtomolar Acting Octapeptide Interacts with Tubulin and Protecots Astrocytes Against Zinc Intoxication;”The Journal of Biological Chemistry; Jul. 2, 2004; vol. 279, No. 27; pp. 28531-28538.
Furman, Sharon, et al.; “Subcellular Localization and Secretion of Activity-Dependent Neuroprotective Protein in Astrocytes;” 2004;Neuron Gilia Biology; vol. 1; pp. 193-199.
GenBank Accession No. AB018327 from the DNA Data Bank of Japan (DDBJ) (released Nov. 17, 1998).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience Letters, Supplement 48 S1-S60, p. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997. Abstracts, vol. 23, Part 2, p. 2249 (1997).
Glazner, G.W. et al. “Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth.”Anat. Embryol.200:65-71 (1999).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience, vol. 7, pp. 235-244 (1996).
Gozes, I. at al. “Stearyl-Norleucine-Vasoactive intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology, vol. 134, pp. 2125 (1994).
Gozes, I. et al. “Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics, vol. 273, pp. 161-167 (1995).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci.USA, vol. 93, pp. 427-432 (1996).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity.”Developmental Brain Research, vol. 99, pp. 167-175 (1997).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience Letters, Supplement 48 S1-S60, p. S21 (1997).
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology, vol. 33, pp. 329-342 (1997).
Gozes, I. et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997. Abstracts, vol. 23, Part 2, p. 2250 (1997).
Gozes, et al., “A Novel Signaling Molecule for Neurop
Alcalay Roy N.
Divinski Inna
Giladi Eliezer
Gozes Illana
Audet Maury
Kilpatrick Townsend & Stockton LLP
Ramot at Tel-Aviv University Ltd.
LandOfFree
Use of ADNF III polypeptides for treating mental diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ADNF III polypeptides for treating mental diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ADNF III polypeptides for treating mental diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742065